Main content

    MMC Available Clinical Trials

    Please follow this link to an updated page

    Breadcrumbs Navigation: Cancer Services > Treatment > Clinical Trials at MMC > You are here: MMC Available Trials


    Note: As of September 2016


    A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer

    A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node Negative Triple-Negative Invasive Breast Cancer.

    NSABP B-51 / RTOG 1304
    A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

    NSABP B-55
    A Randomized, Double-blind, Parallel group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

    RTOG 1119
    Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer

    SWOG 1207 / NSABP B-53
    Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer (Breast Cancer Study – evaluating everolimus with endocrine therapy)

    Back to top


    InterAACT: An International Multicentre Open Label Randomized Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease

    RTOG 0848
    A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma

    A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma

    Back to top


    RTOG 0924
    Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

    SWOG S0931
    EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

    Back to top


    Diet and Physical Activity Change or Usual Care in Improving Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

    A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterus Corpus

    A Randomized Phase III Clinical Trial of Adjuvant Radiation vs. Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initital Radical Hysterectomy and Pelvic Lymphadenectomy

    RTOG 0724
    Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Adjuvant Chemotherapy in High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy

    Back to top

    HEAD & NECK:

    Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA).

    A Randomized Phase II Trial For Patients with p16 Positive, Non-Smoking Associated, Lococregionally Advanced Oropharyngeal Cancer.

    RTOG 0920
    A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

    Back to top


    Alliance A081105
    Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC).

    Alliance A151216
    Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST).

    A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer; Crizotinib vs. Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.

    Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers * Must also be enrolled on A151216.

    A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naïve Patients with Advanced (Stage IV or recurrent), EGFR Mutation Positive Non-Small Cell Lung Cancer.

    Back to top


    Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma.

    Back to top


    Massage Therapy
    The Effect of Oncology Massage Therapy In The Management of Pain In Cancer Patients In An Outpatient Radiation Therapy Setting (MMC radiation patients only)

    Music Therapy
    Effects of Music Therapy Interventions on Pain Perception of Cancer Patients (in hospital only)

    Back to top


    Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma.

    Back to top


    For additional information regarding the above Clinical Trials,
    please contact one of our Cancer Research Coordinators:

    Elise Fredeking, RN, BSN, OCN
    209-526-4500, ext. 6192

    Denise Galbawy, RN, BSN, OCN, CCRC